Decapping by Dcp2 is an essential step in 5′-to-3′ mRNA decay. In yeast, decapping requires an open-to-closed transition in Dcp2, though the link between closure and catalysis remains elusive. Here we show using NMR that cap binds conserved residues on both the catalytic and regulatory domains of Dcp2. Lesions in the cap-binding site on the regulatory domain reduce the catalytic step by two orders of magnitude and block the formation of the closed state, whereas Dcp1 enhances the catalytic step by a factor of 10 and promotes closure. We conclude that closure occurs during the rate-limiting catalytic step of decapping, juxtaposing the cap-binding region of each domain to form a composite active site. This work suggests a model for regulation of decapping where coactivators trigger decapping by stabilizing a labile composite active site.
a r t i c l e s Degradation of mRNA has a crucial role in animal development 1 , cell proliferation 2,3 , differentiation 4 , stress responses 5 , the adaptive immune system 6 and transcript quality control 7 . Removal of the 5′-terminal cap structure by the mRNA decapping enzyme Dcp2 is a critical step in numerous 5′-to-3′ decay pathways including bulk 5′-to-3′ decay 8, 9 , AU-rich element-mediated decay 10, 11 , nonsense-mediated decay (NMD) 7, 12 , miRNA-induced decay [13] [14] [15] and 3′-uridylation [16] [17] [18] [19] . In these pathways, decapping is an irreversible step that exposes the 5′-monophosphate of the RNA body for recognition by conserved 5′-to-3′ exonucleases 20 . Decapping is thus a highly regulated, committed step that sentences an mRNA to destruction.
Regulation of decapping is achieved by a dense network of proteinprotein interactions impinging on the decapping enzyme Dcp2 (refs. 7,14, 21-25) . Though activation of decapping could be accomplished by targeting the decapping complex to a substrate mRNA, recent work revealed that a conformational change in yeast Dcp2 is used to achieve a switch-like response in activity 26, 27 . Crystallographic studies 26, 28 indicate that the conserved N-terminal region of Dcp2 has a bilobed architecture containing a regulatory domain, which binds the essential activator Dcp1, and a catalytic domain of the Nudix hydrolase superfamily 26, 29, 30 (Fig. 1a) . The cocrystal structure of the Schizosaccharomyces pombe Dcp1-Dcp2 complex 26 showed two conformations of Dcp2: one extended and unliganded and the other compact and bound to ATP (Supplementary Fig. 1a ). NMR and kinetic studies revealed an RNA-binding channel that bisects the regulatory and catalytic domains, suggesting that conformational transitions in Dcp2 control an aspect of substrate recognition and catalysis 26, 27 .
Four observations suggest that conversion between open and closed states is required for efficient decapping. First, the regulatory domain and Dcp1 together contribute a factor of 1,000 to the catalytic step and ensure correct bond hydrolysis 27, 31 but are far removed from the active site in the open form of the Dcp1-Dcp2 complex 26 (Supplementary  Fig. 1a) . Second, the regulatory domain and Dcp1 are essential for decapping in budding yeast 9, 28 . Third, the introduction of prolines in the interdomain linker block closure, as detected by small angle X-ray scattering (SAXS), and hinder decapping in vitro 26 . Finally, the proline mutations mimic the effect of a Dcp2 knockout on reporter mRNA half-life in vivo and cause an accumulation of Dcp2 in P bodies 26 . Enlarged P bodies are also a consequence of lesions in a variety of coactivators of decapping, implicating this conformational change in the activation of decapping in vivo 14, 22, [32] [33] [34] . These findings support the notion that conformational changes in Dcp2 constitute a critical, regulated step governing mRNA decapping and transcript stability.
An unresolved question is how closure in Dcp2 is linked to efficient cap hydrolysis. Using the crystal structure of the fission yeast Dcp1-Dcp2 complex as a guide 26 , we show that mutation of conserved residues of the regulatory domain retards the catalytic step and blocks closure. Unexpectedly, a surface of the regulatory domain specifically interacts with m 7 G, whereas the catalytic domain binds multiple nucleotides using different surfaces. We show that Dcp1 enhances the catalytic step by a factor of 10 in vitro, likely by stabilizing the closed conformation 26 . We propose a composite active-site model of decapping where the regulatory domain makes specific interactions with the cap, positioning it for pyrophosphatase chemistry catalyzed by the Nudix domain.
RESULTS

Mutations on the regulatory domain retard the catalytic step
To determine how closure contributes to catalysis, we sought to disrupt the closed crystal form (PDB 2QKM 26 ) and test for kinetic defects. We selected sites along the 31-52 helix of S. pombe Dcp2 involved in the closed-form interdomain interface, mutated them to alanine and a r t i c l e s performed kinetic analyses 27, 35 (Fig. 1a,b ). Because of their superior solubility, we used decapping proteins from S. pombe and cite residue numbers accordingly. Candidate interactions that could stabilize the closed form include a salt bridge between Glu39 and Arg95, an apparent cation-π interaction between Trp43 and Arg167 and a contact between Asp47 and the backbone of Tyr220 (ref. 26) ( Fig. 1b) . We narrowed our focus to Trp43 and Asp47, as a previous alanine scanning study indicated that mutation of these conserved residues resulted in the strongest decapping defects observed on a reporter mRNA in yeast 28 . Alanine substitution at positions 43 and 47 attenuated decapping activity in our single-turnover kinetic assay, consistent with previous in vitro endpoint assays 28 (Fig. 1c ). Mutation at Trp43 or Asp47 reduces the catalytic step (k max ) by a factor of 20 or 100, respectively, whereas K M was nearly unchanged ( Fig. 1d and Table 1 ). Given the location of Trp43 and Asp47, the attenuation of the catalytic step is likely achieved by destabilizing the active species.
Mutations on the regulatory domain block closure
The kinetic analyses above cannot distinguish between defects in conformational changes or chemistry, as both are proposed to occur in the catalytic step. As such, we turned to SAXS to directly test the effect of the mutants on conformational changes in Dcp2. It was previously established that a compaction of the Dcp1-Dcp2 complex occurs in the presence of ATP or substrate analogs 26 . We reproduced these data on a C-terminal deletion construct (1-243) that is more amenable to solution NMR spectroscopy but has the same activity in vitro ( Fig. 2a and Supplementary Fig. 1b) . The distance distribution function P(r) reveals a compaction in the presence of the cap analog m 7 GpppA, which is small but reproducible (n = 3) ( Fig. 2b) . In response to nucleotide addition, the radius of gyration R g shrinks from 31.4 ± 1 Å to 28.1 ± 1 Å, and the maximum interatomic distance D max is reduced from 135 ± 10 Å to 105 ± 10 Å in the unbound and liganded experiments, respectively. The region of P(r), which changes upon ligand addition (60-100 Å), is similar to the region that changes between the computed P(r) curves from the open and closed crystal forms ( Supplementary Fig. 1c-e ). Differences between the apo solution scattering and open crystal form ( Supplementary Fig. 1c ) or between the liganded solution scattering and closed crystal form ( Supplementary Fig. 1d ) likely result from averaging due to a heterogeneous population, potentially including a mixture of the open and closed crystal forms or alternative states.
In contrast to the compaction observed in wild-type (WT) Dcp1-Dcp2, SAXS analysis of the Dcp1-Dcp2 W43A mutation shows no change in R g or the distance distribution function between 60 and 100 Å upon addition of cap analog (Fig. 2c) . The D47A mutation did not have a visible effect on the SAXS distance distribution function (data not shown). We therefore conclude that mutation at Trp43 alters the conformational states accessible to Dcp2 and that Asp47 may affect either the chemical or conformational step, or both.
Dcp1 enhances the catalytic step
Previous kinetic studies of Saccharomyces cerevisiae proteins indicated that Dcp1 and the regulatory domain of Dcp2 contribute a Figure 1 Mutants along the interdomain interface in the closed crystal form attenuate the catalytic step of decapping. (a) Dcp2 consists of an N-terminal regulatory domain (1-94, purple), a catalytic domain of the Nudix superfamily (95-243, green with the Nudix motif in red) and a large, nonconserved C-terminal region of unknown function (244-741, brown). A sequence alignment is provided for residues 30-50 of Dcp2, with absolutely conserved residues highlighted in yellow. For residues 30-50, the solventaccessible surface area (SASA) is shown on a relative scale from buried to exposed in both the open (o) and closed (c) crystal forms (for details, see Online Methods). (b) The interface between the regulatory domain (purple) and the catalytic domain (green) in the closed, ATP-bound crystal structure is shown with sites of mutation highlighted (PDB 2QKM 26 ). Gold, Dcp1; red, catalytic Nudix helix of Dcp2. (c) Observed rate constants for decapping assays of various constructs as marked. Solid lines are fitted to a rate equation appropriate for singleturnover kinetics, where enzyme is in excess of substrate 35 (see Supplementary Note). Error bars, s.e.m. for the rate measured in two or more independent experiments. (d) The rate of the catalytic step (k max ) is plotted on a log scale for selected interface mutants; error is s.e.m. a r t i c l e s factor of 1,000 to the catalytic step of decapping 27 . Unlike the decapping proteins from S. cerevisiae, Dcp1 and Dcp2 from S. pombe can be expressed in Escherichia coli and purified separately 28 , allowing us to directly quantify the catalytic enhancement by Dcp1. Dcp1 stimulates the catalytic step (k max ) by 10 times, with only a small change in K M (Fig. 1c,d and Table 1 ). We only detected nucleotide-driven closure of S. pombe Dcp2 by SAXS in the presence of Dcp1, suggesting that it may affect the conformational equilibrium that could manifest in this rate enhancement 26 . Therefore, the enhancement previously measured 27 consists of a factor of 10 from Dcp1 and 100 from the regulatory domain.
The ATP-bound and active forms may be distinct
The rationale for mutation at Trp43 is its apparent cation-π interaction with Arg167 in the ATP-bound closed conformation 26 (Fig. 1b) . However, mutation of the nonconserved residue Arg167 to glutamine ( Fig. 1c,d) or alanine has no effect on decapping in vitro 26 . Consistent with the kinetic data, R167Q transitions into a compact state upon addition of m 7 GpppA (Fig. 2d) . Differences in the R167Q distance distribution functions ( Fig. 2d ) compared to WT (Fig. 2b) are largely due to a difference in unliganded R167Q versus unliganded WT Dcp2. Therefore, Trp43 retards the catalytic step by blocking closure independently of Arg167, and conversely, Arg167 is not involved in stabilizing the active conformation of Dcp2. This suggests that the interdomain interface in the active form may be different than that observed in the ATP-bound crystal structure 26 .
The regulatory domain harbors a binding site for cap
We previously determined that substrate RNA is bound by the catalytic domain of S. cerevisiae Dcp2 and that N7-methyl cap is specifically recognized during the catalytic step 27 . However, it was not possible to address the structural foundation of this effect due to the limited solubility of budding yeast Dcp2 constructs 27 . Because closure is promoted by nucleotide, we reasoned that formation of a compact, active form was likely driven by direct contacts between the two domains and cap. Therefore, we used a fragment-based strategy to test the ability of each domain of S. pombe Dcp2 to bind m 7 GDP product and a panel of nucleotides by NMR, starting with the regulatory domain (residues 1-94, Fig. 1a ). Unexpectedly, we found that the regulatory domain has an evolutionarily conserved binding site for m 7 GDP (Fig. 3a,b) . We detected strong chemical-shift perturbations at both the Trp43 and Asp47 positions and the surrounding 31-52 helix (Fig. 3c,d and Supplementary Fig. 2a ). The HSQC titrations were fitted well by a two-state binding model that is used throughout to calculate dissociation constants, consistent with the colinearity of the chemical-shift perturbations (Fig. 3c,d and Supplementary Fig. 2b) . Fitting of HSQC titrations for the Trp43 indole and Asp47 backbone amide yields a K d for m 7 GDP of roughly 12 mM, suggesting a concerted binding process ( Supplementary Table 1 ). Direct binding of cap by the regulatory domain suggests how substrate binding may stimulate closure.
We next tested the specificity of this binding site by titrating different nucleotides against the domain, and we found that GDP a r t i c l e s bound weakly to the same site (Fig. 3e,f and Supplementary Fig. 2c ) and that neither ATP nor other nucleoside diphosphates bound to this site ( Supplementary Fig. 2d and data not shown). Quantification of the data shows that the GDP K d is weaker at ~40 mM ( Supplementary  Fig. 2e and Supplementary Table 1 ). Therefore, this site is specific for the guanine base and has enhanced affinity for the N7-methylated form. Critically, mutation of Trp43 to alanine blocks m 7 GDP binding, directly implicating Trp43 in the binding process and suggesting that mutation at Trp43 blocks closure by decoupling the regulatory domain from cap recognition (Supplementary Fig. 2f ). As m 7 GDP is a product of the decapping reaction, it is possible that its binding to the regulatory domain is different than that of the substrate RNA cap. Therefore, we tested binding of the cap analog m 7 GpppA and found that it binds the same surface with nearly identical affinity to that of m 7 GDP ( Supplementary Fig. 3 and Supplementary Table 1 ). In contrast, ApppA does not bind the regulatory domain (Supplementary Fig. 4) . These data indicate that the addition of adenine, which would correspond to the first transcribed nucleotide of the mRNA, does not affect the recognition of m 7 G by the regulatory domain.
The catalytic domain binds m 7 G and ATP at different sites
If there is a ligand-dependent coupling between the two domains, then the catalytic domain should also bind nucleotide. To test this we again used HSQC titration to assess the nucleotide binding ability of the catalytic domain (residues 95-243 of S. pombe Dcp2, Fig. 1a) . Three regions were perturbed upon addition of nucleotide: the convex dorsal surface (residues 224-243), the ATP-binding pocket in the crystal structure of S. pombe Dcp1-Dcp2 (residues 116-122, 129 and 220-222 (ref. 26)) and the catalytic helix (residues 136-148). There is a clear difference in the binding profile of m 7 GDP and ATP for these regions (shifts depicted on PDB 2QKM 26 , Fig. 4 and Supplementary  Fig. 5 ). The dorsal surface was perturbed upon addition of either ATP or m 7 GDP (Fig. 4d,f) . This region is positively charged and was shown to bind the RNA body nonspecifically, consistent with its lack of specificity for nucleotide 27 . Similarly, the ATP-binding pocket of the protein is the canonical substrate binding region in Nudix hydrolases 29 and binds both nucleotides tested. We directly tested the contribution of the γ phosphate on ATP by titrating ADP against the catalytic domain and found results similar to those with ATP but with reduced affinity, consistent with the interaction being driven by electrostatics ( Supplementary Fig. 6 and Supplementary  Table 1 ). Notably, there is agreement between the ATP binding site in the closed crystal state 26 , the RNA-binding channel determined in a previous study 27 and the regions detected by NMR chemical-shift perturbation in this work.
In contrast to the dorsal surface and the ATP binding pocket, the catalytic helix was selectively perturbed upon addition of m 7 GDP but not ADP or ATP (Fig. 4a,b,e,g and Supplementary Fig. 6 ). Binding of m 7 GDP also caused perturbations around the catalytically essential residue Glu192, pointing at a potential interaction between Glu192 and cap or remodeling of the 161-194 loop that is not detected by NMR in the presence of ATP or ADP (Figs. 1b and 4a and Supplementary  Fig. 5a ) The previously determined location of the 5′-phosphate of the RNA body places the cap close to the catalytic helix, which is consistent with the perturbations we see upon addition of m 7 GDP. Moreover, we previously showed that residues in the catalytic helix are perturbed by nonhydrolyzable capped RNA but not 5′-hydroxyl RNA 27 . In conclusion, the catalytic helix has a specific binding site for cap, whereas the dorsal surface binds the RNA body.
We selected two probes for quantification: the conserved Nudix motif residue Glu146 on the catalytic helix and Lys235 on the RNAbinding region. ATP binds the RNA-binding helix (Lys235) with a K d of ~5 mM but not does not detectably bind the catalytic helix ( Supplementary Fig. 5d and Supplementary Table 1) . In contrast, m 7 GDP binds to the catalytic helix (Glu146) with a K d of 12 mM but only weakly perturbs the RNA binding helix (Supplementary Fig. 5c and Supplementary Table 1 ). Unexpectedly, the affinity of m 7 GDP for the catalytic helix and regulatory domain are nearly identical, hinting at a concerted binding process in the two-domain protein. These results suggest that Dcp2 has a composite active site that forms as a result of closure, with cap-specific contacts formed by the regulatory and catalytic domains.
DISCUSSION
In this work, we uncovered the role of conformational changes in the catalytic mechanism of Dcp2 and the driving force for conversion into the active form. Dcp1 and the regulatory domain contribute factors of 10 and 100 to the catalytic step, respectively, by modulating conformational states of Dcp2 (Fig. 1) . The regulatory domain enhances a r t i c l e s the catalytic step by specifically binding m 7 G on a conserved surface surrounding Trp43 and Asp47 (Figs. 1 and 3 and Supplementary  Fig. 3) . Lesions in the cap-binding site block closure and retard the catalytic step by up to two orders of magnitude ( Figs. 1 and 2) , consistent with the severe decapping defect in vivo upon mutation of Trp43 or Asp47 (ref. 28 ). These findings indicate that conversion to the active form of Dcp2 is driven through specific cap recognition by the regulatory domain and suggest that the active form harbors a composite active site with both domains sandwiching the cap. Nudix family members contain a conserved catalytic motif with additional insertions or domains conferring substrate specificity 29, 36 . Dcp2 conforms to this paradigm, with the catalytic domain performing chemistry and the regulatory domain providing specificity by accelerating catalysis on N7-methyl-capped substrates.
Notably, the addition of m 7 GDP perturbs residues on the conserved, catalytic Nudix helix, whereas ATP and ADP do not ( Figs. 4 and 5a) . The regulatory domain may contribute to catalysis by positioning substrate, as it is required to hydrolyze the correct phosphate bond 31 . High-resolution structural studies of Dcp2 in complex with substrate will be required to confirm this prediction.
The cap-bound conformation is different than the ATP-bound closed form for four reasons. First, the cap-binding residues Trp43 and Asp47 of the regulatory domain are buried in the closed structure and do not contact ATP 26 (Fig. 1a,b) . Second, the regulatory domain and catalytic helix both bind m 7 GDP by NMR but are separated by ~20 Å in the closed crystal structure 26 (Fig. 5a and Supplementary  Fig. 1a ). Third, Trp43 forms an apparent cation-π interaction with Arg167 of the catalytic domain, but mutating Arg167 to glutamine or alanine does not affect closure or decapping in vitro 26 (Fig. 1b-d) . Fourth, in the closed, ATP-bound form of Dcp1-Dcp2, nonconserved residues 244-266 of the catalytic domain fold into a helix that interacts with the regulatory domain, yet deletion of these residues has no effect on decapping or closure in vitro 26, 28 (Supplementary   Fig. 1b) . It is unclear whether the ATP-bound form represents an on-or off-pathway state, but it is accessible in solution, as ATP causes closure 26 . Dcp2 may assume different conformations from specific or nonspecific interactions with substrate, as described for other nucleic acid-binding proteins 37, 38 . Given the composite active site suggested here and the previous crystal structure with open and closed conformations 26 , we conclude that the native energy landscape of Dcp2 is rugged with multiple accessible states depending on the ligand. Activation of decapping by closure was postulated to be a late step in 5′-to-3′ decay that is promoted by coactivators 26, 33 . Dcp2 with prolinehinge mutants blocking closure still localizes to P bodies, but the decay of messages is blocked 26 . Large P bodies containing Dcp2 and decay substrates are a hallmark of stalled decay complexes or overwhelmed decay machinery and are observed in coactivator mutants 22, 32, 34 . The proline-hinge mutants also cause a dramatic defect in bulk mRNA decay both in vitro and in vivo 26 . The conformational change detailed here is likely part of this late, regulated step, as mutation at Trp43 mimics the defect of the proline-hinge mutants on closure in vitro and in vivo 28 . Therefore, closure and formation of the composite active site may couple decapping to stimulation by coactivators.
Our results are consistent with a model of decapping by Dcp2, in which the catalytic step consists of at least two substeps, beginning with isomerization to the active form ( Fig. 5b) followed by the chemical step 39 (Fig. 5c and Supplementary Note) . In the open form, the active site is incomplete, resulting in inefficient decapping ( Fig. 5b and Supplementary Fig. 1a) . Cap recognition by both domains induces closure and forms a composite active site, allowing for efficient decapping (Fig. 5c) . Previous experiments revealed that 5′-monophosphate product RNA and nonhydrolyzable substrate RNA bind with the same affinity, suggesting cap recognition and closure occur after binding 27 . Dcp1 may accelerate the catalytic step by stabilizing the composite active site or enhancing the rate of closure. Like Dcp1, coactivators of decapping such as the Edc proteins in yeast 40, 41 , the NMD factors Upf2 and Upf3 (ref. 33) , the heptameric Lsm1-Lsm7 complex 32 , Pat1 (ref. 32 ) and others may stimulate decapping by altering this conformational equilibrium. This is similar to regulation of DEAD-box helicases by cofactors that couple conformational changes to ATP hydrolysis using a bipartite active site 42, 43 . The scavenger decapping enzyme DcpS also uses a composite active site to decap 3′-to-5′ exosomal decay products but is different in fold, chemistry and regulation 44, 45 . For Dcp2, coactivators have a critical role in regulation, and the new understanding of the active form presented here motivates further mechanistic studies to determine how regulation is achieved in different 5′-to-3′ mRNA decay pathways.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. 
